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ABSTRACT 
 
 
Introduction: Colposcopy and tissue biopsy remain the gold standard for diagnosing 
vulvar intraepithelial neoplasia (VIN). Vulvar colposcopy is fairly nonspecific. As a 
result, many women undergo unwarranted painful biopsies. Vulvar cytology, which is 
relatively painless, inexpensive and allows a larger area to be sampled, may likely reduce 
false negative diagnoses. However, previous cytological studies that used conventional 
methodologies were largely unsuccessful in diagnosing VIN. In this study, liquid based 
cytology and HPV typing by PCR have been assessed as possible alternatives to biopsy 
for follow-up surveillance of women treated for VIN. 
 
Methods: Women with a history of VIN and a control group were recruited from a 
colposcopy clinic. Clinically suspicious lesions and normal vulvar tissue were vigorously 
brushed and the sample collected in PreservCyt® fluid for cytologic examination and for 
HPV-typing with a multiplex PCR assay, using primers designated PGMY09/11. 
Samples (N=82) were obtained from 52 lesions clinically suspicious for VIN, 15 controls 
from the same women in areas of the vulva with no clinical abnormality, and 15 controls 
from women with no current clinical evidence or past history of VIN. Concurrent tissue 
biopsies were obtained, immediately after brushing, from the 52 clinically suspicious 
VIN lesions. A single pathologist read and interpreted the biopsy samples. To ensure 
unbiased testing, cytology and HPV analyses were performed at separate independent 
laboratories by professionals blinded to clinical findings and biopsy results. Cytology was 
coded as negative, ASCUS, VIN I, VIN 2, or VIN 3. Specificity, sensitivity, and 
predictive values of cytology and HPV for VIN were calculated. Fisher’s exact was used 
to determine associations between HPV and cytology. Logistic regression was done to 
determine if cytology or HPV predicted tissue biopsy results. 
 
Results:  Vulvar samples (N=82) were collected from 48 women aged 19-65 who 
participated in this study. Histology results of the 52 lesions clinically suspected as VIN 
were reported as follows: VIN I (n=33), VIN 2/3 (n=13), benign (n=4), contact dermatitis 
and condyloma (n=1 each). Ninety percent of the vulvar samples were adequate for 
cytologic evaluation, but only 72% of samples had adequate cellularity for HPV testing. 
Sensitivity, specificity and positive predictive value (PPV) of vulvar cytology for 
recurrent VIN were 95%, 15% and 65% respectively. PCR for HPV, when independently 
correlated with histology, had, 62% sensitivity, 85% specificity and 89% PPV for VIN. 
No significant associations were found between cytology and HPV (p=0.3559). Neither 
cytology nor HPV predicted pathological diagnosis of VIN. 
 
Conclusion: By vigorous brushing, it is possible to obtain an adequate cellular sample 
from the vulva for cytologic and/or molecular evaluation for HPV. The specificity for 
VIN at cytology was not satisfactory for use as a clinical alternative to biopsy to detect 
recurrent VIN. This may be due to the small sample size, difficulty in accurately grading 
vulvar dysplasia at cytology, and possible differences in cytomorphologic criteria for 
diagnosing dysplasia in the vulva as compared to the cervix. This study will be further 
refined with the development of more reproducible consensus criteria for cytologic 
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evaluation of VIN. A larger number of participants could shed more light on the 
significance of cytology with or without HPV testing as an alternative to tissue biopsy for 
follow up of patients with VIN.   
vi 
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CHAPTER 1.  INTRODUCTION 
 Vulvar cancer is a rare disease traditionally found in older women with a peak 
incidence in the 6th and 7th decade (Sturgeon, Brinton, Devesa, & Kurman, 1992). Over 
the last ten to twenty years, there has been a significant increase in vulvar intraepithelial 
neoplasia (VIN), a family of lesions which are precursors to vulvar carcinoma. VIN can 
be due to human papillomavirus (HPV), called undifferentiated VIN, or due to an 
epithelial disorder, known as differentiated VIN. Undifferentiated VIN, related to HPV is 
typically observed in younger women, defined in most literature as less than the age of 
50. The increase in VIN has been most dramatic among younger women and is attributed 
to several factors, most noticeably increased exposure to HPV (Jones, Baranyai, & 
Stables, 1997; Joura, Losch, Haider-Angeler, Breitenecker, & Leodolter, 2000). VIN also 
has a high rate of recurrence. The current standard of care therefore dictates close follow-
up with colposcopic examinations and periodic biopsies to rule out recurrence (Sturgeon 
et al., 1992). However, even with the aid of a colposcope, it is difficult to distinguish 
between benign lesions resulting from infections, various skin conditions or scar tissue 
from neoplastic or dysplastic lesions (Likes, 2009). Therefore, all lesions are typically 
subjected to tissue evaluation through biopsies. Tissue biopsies are invasive and painful 
and women with VIN describe them as stressful and anxiety provoking (Likes, Russell, & 
Tillmanns, 2008).  
 
A new method for monitoring women with vulvar lesions is needed that would be 
less painful and anxiety-laden and thereby enhance patient compliance, follow-up, and 
successful treatment.  The Papanicolaou test (Pap smear), which has been highly 
successful in the triage of patients for cervical cancer, has failed to show similar success 
in pilot studies triaging vulvar neoplasia and dysplasia. These studies employed 
conventional sampling techniques and cytologic sample processing methodology. New 
liquid based cytologic techniques and ancillary molecular markers have shown increased 
efficacy in detecting cervical neoplasia and therefore could potentially allow efficient and 
accurate evaluation of VIN without the pain and anxiety associated with tissue biopsy. 
 
Background and Significance 
 The Pap test, which involves collection of cells from the mucosal surface of the 
cervix for microscopic study, has been widely successful in detecting cervical 
malignancy and premalignant conditions. Previous attempts to use cytologic methods to 
identify VIN have been largely unsuccessful due to problems with suboptimal sample 
collection and drying of the cellular material, thus interfering with optimal diagnostic 
evaluation (Dennerstein, 1968, 1988; Nauth, 1986; Nauth & Boger, 1982). These reports 
also cite poor correlation between vulvar cytology and biopsy results. However, these 
studies did not employ modern collection devices or current and more optimal liquid 
based cytologic processing methods. Even in the most recent study employing vulvar 
cytology (Bae-Jump, Bauer, & Van Le, 2007), only 6 of the 50 patients were evaluated 
using the ThinPrep® technique (Cytyc Corporation Marlborough, MA) and the 
specimens were collected using the spatula sampling device rather than the more modern 
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brush or broom-type collection devices.  In addition, this study utilized a retrospective 
chart review without established consistency in sampling of the lesion. Cytology, 
specifically cervical cytology, is a technique familiar to most health care practitioners. 
Vulvar cytology can be performed using the same equipment as Pap smears. After 
properly defining the technique and the mechanics of the procedure, vulvar cytology 
would require a less sophisticated skill set than tissue biopsy and would be more readily 
available to practitioners. It can be hypothesized, that using vulvar cytology would allow 
for a wider screening of abnormal vulvar lesions within a faster time frame than if the 
health care provider referred the patient to a specialist for tissue biopsy. Therefore, pre-
invasive lesions could be found with greater ease before progression to cancer occurs 
resulting in decreased morbidity and mortality from vulvar cancer. 
 
Purpose of the Study 
The standard diagnostic procedure for VIN remains visualization and biopsy.  
However innovative and less invasive sampling and evaluation techniques could be 
introduced, which are likely to improve patient compliance without compromising 
diagnostic accuracy.  The use of liquid-based techniques allows for cytologic 
interpretations to be made from these vulvar lesions without actually obtaining tissue 
through puncture.  Therefore, the purpose of this study was to determine the feasibility of 
developing a protocol for cytologic sampling of vulvar lesions and to evaluate the 
efficacy of vulvar cytology in conjunction with Human Papillomavirus (HPV) testing as a 
valid method for following women treated for vulvar intraepithelial neoplasia (VIN). 
 
Specific Aims 
In contrast to previous studies, this feasibility study utilized a nylon brush and 
saline to moisten and exfoliate cellular material from the lesions.  The cellular material 
was then immersed into PreservCyt® solution for ThinPrep processing, which is believed 
to enhance the adequacy of specimens and be more effective in the identification of 
cervical cancer precursors than other methods.  A second sample was collected for HPV 
typing using the polymerase chain reaction (PCR) method.  The specific aims and 
research questions of this study were: 
 
 
Specific Aim 1 and Research Questions 
 
To determine the feasibility of a protocol for cytologic sampling of vulvar lesions. 
 
1.1 Does the vulvar sampling technique provide adequate cellularity for 
cytologic examination? 
1.2 What is the sensitivity of vulvar cytology for detecting VIN? 
1.3 What is the specificity of vulvar cytology for detecting VIN? 
1.4 What are the negative and positive predictive values of vulvar cytology for 
detecting VIN? 
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Specific Aim 2 and Research Questions 
 
To evaluate the efficacy of vulvar cytology in conjunction with Human 
Papillomavirus (HPV) testing as a valid method for following women treated for vulvar 
intraepithelial neoplasia. 
 
2.1 What is the relationship between vulvar cytology results and HPV results? 
2.2 Can HPV testing in combination with vulvar cytology, while controlling for 
age, be utilized as a triage tool for tissue biopsy results? 
2.3 What is the accuracy of PCR analysis for HPV as a predictor of vulvar 
intraepithelial neoplasia?  
2.4 If an association is found between cytology/HPV and tissue biopsy results, 
then determine if cytology in conjunction with HPV testing predict the 
biopsy outcome? 
 
 
Operational Definitions 
 
Vulvar lesion —A clinically apparent vulvar lesion that may be flat or raised, 
discolored, and/or ulcerated OR an area of acetowhite change after application of acetic 
acid. 
 
Vulvar intraepithelial neoplasia (VIN)—A precancerous condition of the vulva 
diagnosed through vulvar biposy. 
 
Human papillomavirus (HPV)—A virus that interferes with the cell’s ability to 
prevent excessive growth and may potentially lead to precancerous and cancerous 
conditions. HPV is detected through polymerase chain reaction (PCR). 
 
ThinPrep®—A liquid based process for cytologic interpretation. 
 
PreservCyt®—A specimen collection fluid for preservation of cytologic material 
for up to 6 weeks at 15-30°C. 
 
Polymerase chain reaction (PCR)—A key technique in molecular genetics that 
permits the analysis of any short sequence of DNA (or RNA) without having to clone it. 
PCR is used to reproduce (amplify) selected sections of DNA.  
 
Gold standard—For comparison of the diagnostic tests under evaluation was 
tissue biopsy or in absence of tissue biopsy, HPV typing. 
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Assumptions 
 
The framework of this study is grounded on the following assumptions. 
 
• The “gold standard” for diagnosis of VIN is vulvar biopsy. 
• Participants who are HR HPV negative do not have VIN. 
• If the “gold standard” is not available, then HPV testing is an appropriate 
substitute to determine that a woman would not have VIN 
• Participants who are healthy controls, and have a negative cytology, do not 
have VIN. 
• Factors influencing the method used for diagnosis include: patient discomfort, 
risks of the procedure, cost, accuracy, distress, and ease of collection.  
 
 
Limitations 
 
The following limitations were considered during the conduct and in interpreting 
the outcomes of this study:  Tissue biopsy was not collected on those who were healthy 
controls. 
 
 
Conceptual Model: Linking HPV Changes to the Clinical Pathway in VIN 
 
The conceptual model was constructed using relevant published literature and 
knowledge based on clinical experience in the study population (Figure 1). The model 
depicts the cellular changes from HPV, the development of VIN, and the detection of 
these changes. The details of this model are described in the following sections.  
 
 
Human Papillomavirus 
 
Papillomavirus are a diverse group of DNA-based viruses that typically affect the 
epithelium in humans. Over 100 types of HPV have been identified with each infecting 
specific epithelial sites (Longworth & Laimins, 2004). There are two main HPV genere,  
alpha and beta.  Beta papillomavirus affects cutaneous areas whereas alpha 
papillomavirus infects genital and mucosal surfaces. HPV’s are broadly categorized into 
high risk (HRHPV), intermediate risk (IR HPV), and low risk (LR HPV) types. HR HPV 
are the types most commonly associated with the development of cancer (Kagie et al., 
1997). LR HPV and IR HPV are rarely implicated in cancer development and more 
commonly associated with the development of warts.  HR HPV infection is commonly 
observed and although it has the potential to cause cancer, the association of HR HPV 
infection with cancer is not inevitable.   
 
HPV infection is a non-lytic infection and thereby can escape recognition by the 
host’s immune system (Kanodia, Fahey, & Kast, 2007). HPV is believed to enter the host 
through micro-abrasions on the epithelial surface.  The HPV virion establishes itself in 
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Figure 1. Conceptual model 
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the basal  layer of the epithelium and enters the epithelial cells through endocytosis. The 
HPV genome is comprised of 6 early proteins (E1, E2, E4, E5, E6, E7) and two late 
proteins (L1 & L2).  E6 and E7, the first genes to be expressed, are the major 
transforming genes and cause an increase in cellular division (Likes & Itano, 2003; 
Longworth & Laimins, 2004). As these cells divide, they carry the HPV DNA with them. 
E1 possesses DNA-dependent ATPase and ATP dependent helicase activity which assists 
in unwinding of the host DNA. E1 and E2 are responsible for viral replication.  
 
This replication process appears to occur during the S-phase of the cell cycle. E4 
and E5 encode a protein required for the final stage of replication. The viral oncogenes, 
E6 and E7 are thought to modify the host’s cell cycle to continue viral genome 
replication by driving it into the S-phase. The E5 protein is capable of inactivating the 
tumor suppressor gene p21 while E6 combines to the tumor suppressor gene p53 and 
targets it for destruction. In addition, E7 binds to the tumor suppressor gene Rb1 or p107 
and inactivates it leading to deregulated growth control in the epithelial cells.  With the 
combined action of these proteins, the restraint of the cell-cycle progression is lost and 
normal terminal differentiation does not occur.  The cell does not respond to the cellular 
DNA damage and secondary mutations are allowed to go unchecked. The relative 
thickness of epithelium increases as the grade of neoplasia increases and the extent of 
differentiation decreases (Doorbar, 2006). L1 and L2 produces viral like particles and are 
expressed in the differentiation cycle of the keratinocytes and other HR HPV affected 
epithelial cells. In skin, these virus- like particles are shed with the dead skin cells. The 
HPV life cycle is represented in the model with the circular structure that depicts the 
various proteins as described above.  
 
 
Vulvar Intraepithelial Neoplasia 
  
Vulvar Intraepithelial Neoplasia includes two types of lesions, differentiated and 
usual type. Differentiated VIN is not related to HPV and typically arises in a background 
of lichen sclerosis or squamous cell hyperplasia. This type of VIN usually occurs in 
women over the age of 50 (Stroup, Harlan, & Trimble, 2008). Differentiated VIN has 
been found to chronically progress from oxidative damage to genetic instability, atypia, 
and finally cancer (Kagie et al., 1997; Lin et al., 1998). This type of VIN represents 
approximately 20% of all VIN cases and will not be represented in this study. Thus, the 
overlap of VIN and HPV in the conceptual model for this study is not complete since not 
all VIN’s are caused by HPV. 
 
This study will focus on usual type VIN. Usual type VIN is typically related to 
HR HPV types, particularly 16, 18, 31, and 33 (Vinokurova et al., 2005). VIN usual type, 
is associated with warty and basaloid squamous carcinomas which are HPV related 
tumors (Stroup et al., 2008). 
 
 The gold standard for the diagnosis of VIN is tissue biopsy. However, historically 
vulvar cytology was used as a triage tool prior to biopsy. However, this practice has been 
largely abandoned. The current study re-evaluates the use of vulvar cytology. In the 
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conceptual model, biopsy and cytology are depicted as scales in that this study will 
determine if cytology is equivalent to biopsy or appropriate as a triage tool prior to 
biopsy. These tests may be used for detection, monitoring, and for the evaluation of 
treatment in women with VIN. This is depicted as cyclic since VIN has a high recurrence 
rate and therefore, the diagnostic method chosen will continually be utilized for the 
detection of recurrent disease, monitoring of disease, and evaluating treatment 
effectiveness.  
 
The outer circle in the model depicts the assumed influences on the diagnostic 
method chosen. A hierarchical classification system for the clinical endpoints of 
diagnostic technology assessment has been developed. Pearl developed a system that 
utilizes 6 categories for investigation of outcomes: technical efficacy, diagnostic accuracy 
efficacy, diagnostic thinking efficacy, therapeutic efficacy, clinical outcome efficacy, and 
societal efficacy (Pearl, 1999) This study focuses on the first two categories of this 
hierarchical model; technical efficacy and diagnostic accuracy efficacy. These two 
categories are depicted in the outer ring in orange highlighted boxes. Technical efficacy 
will be evaluated through feasibility of the method by determining if adequate numbers 
of cells are obtained for evaluation.  Diagnostic accuracy efficacy will be evaluated by 
the sensitivity, specificity, and predictive values of vulvar cytology. Additional factors 
that influence the testing method include: discomfort, risks, costs, distress, and ease of 
collection. Vulvar cytology is assumed to cause less discomfort and fewer risks since it is 
not an invasive procedure. This is felt to lead to less distress. In previous focus groups, 
women with VIN identified biopsies as painful and anxiety provoking  (Likes et al., 
2008). If cytology is found to be an appropriate method for clinical management of these 
women, this aspect of the model should be evaluated. Vulvar colposcopy with tissue 
biopsy costs approximately $350.00 whereas cytology is approximately $35.00. Further 
studies will need to be conducted on the cost-benefit of using cytology. In addition, 
vulvar cytology requires less technical skill and equipment to perform and should be 
more readily available for use by healthcare providers, thus making it a feasible method 
for clinical evaluation. These additional influences in the model will need to be analyzed 
if the data from this study is in support of using cytology. 
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CHAPTER 2.  REVIEW OF LITERATURE 
 Several studies have reported that vulvar cancer and its precursor, vulvar 
intraepithelial neoplasia (VIN) are increasing (Joura et al., 2000; Judson, Habermann, 
Baxter, Durham, & Virnig, 2006; Maclean, 2006; Sturgeon et al., 1992). Over the last 
several decades, the incidence of VIN has doubled in all age groups and tripled in those 
under the age of 50 (Joura et al., 2000; Sturgeon et al., 1992). In addition, it was found 
recently that the incidence of vulvar cancer increased by 20% in the United States 
between 1973 and 2000 (Judson et al., 2006). This increase in VIN and vulvar cancer is 
concerning, however more alarming is the doubling of cases of vulvar cancer in women 
under the age of 50 years (Maclean, 2006). This increase is postulated to be due to the 
increased rate of human papillomavirus (HPV), a sexually transmitted virus. A vaccine 
has been developed to cover HPV types 6, 11, 16, and 18. The advent of the vaccine 
holds much promise for the prevention of this disease; however studies have yielded 
variable results on the types of HPV implicated in VIN and vulvar cancer. One study 
found 84% of high grade VIN (HGVIN) was due to HPV types 16/18. In addition, of the 
65% of vulvar cancers related to HPV, approximately 55% were due to HPV 16/18 
(Insinga, Dasbach, Elbasha, Puig, & Reynales-Shigematsu, 2007). Skapa found similar 
results, but also found HPV 33 and HPV 45 can be implicated in approximately 27% of 
vulvar cancers and 20% of VIN lesions (Skapa et al., 2007). Screening measures, as well 
as preventive measures, are paramount in this disease process as rates of VIN and vulvar 
cancer are increasing. 
 
 The gold standard for diagnosis of vulvar cancer and VIN is tissue biopsy of the 
vulvar lesion.  Women with VIN present with a high recurrence rate noted to range from 
18-52% (Hillemanns, Wang, Staehle, Michels, & Dannecker, 2006; Jones, Rowan, & 
Stewart, 2005; Thuis, Campion, Fox, & Hacker, 2000). Women with VIN are typically 
followed every 3 to 6 months with vulva colposcopy. If an abnormal lesion is found, the 
gold standard is tissue biopsy. Vulvar colposcopy is fairly nonspecific with many non-
neoplastic disorders presenting with aceto-white changes that may mimic VIN. Many 
women undergo vulvar biopsy for conditions that may not warrant tissue biopsy. 
Historically, vulvar cytology would have been used as a triage tool; however this method 
has been abandoned for multiple reasons as previously stated. Vulvar cytology remains 
appealing since it can sample a larger area rather than one 3-4mm area taken by a punch 
biopsy and therefore may result in less false negatives. Vulvar cytology is also less 
expensive, less invasive and may spare some women from the need of a painful tissue 
biopsy. The main issues that need to be addressed are: what is the most appropriate 
collection technique to obtain an adequate sample, how does vulvar cytology compare to 
the gold standard, and where in the clinical pathway is vulvar cytology most appropriate? 
This paper will review the literature in regard to these questions. However the literature is 
sparse and most of it is outdated. In addition, newer technologies, such as liquid-based 
cytology have been developed since most of these studies. Liquid-based cytology offers 
the ability to collect a sample with less obscuring material. In addition, air-drying that 
occurred with previous slide-based technology does not occur in liquid-based cytology. 
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Collection Techniques 
 The first published account on vulvar cytology was reported in 1950 but focused 
on the classification of vulvar smears (Carter, 1950). Dennerstein published the first 
account of a vulvar cytology collection technique eighteen years later (Dennerstein, 
1968). He noted that in order to adequately sample the vulva, the tissue should be scraped 
with a scalpel after soaking the area with a saline swab. Since then, much debate has 
occurred over the collection technique that would yield adequate cells for examination. In 
1988, Dennerstein compared three different collection techniques (Dennerstein, 1988); a 
scalpel (as he advocated earlier), a swab stick, and a spatula. The scalpel method was 
found to be the most diagnostically useful. Ayala and Ayal used the scalpel technique in 
their study on vulvar terminology with a reported 1% unsatisfactory rate (Ayala et al., 
1976).  The most recent published study on vulvar cytology also utilized the scalpel 
method with fixation to a slide and also included 6 cases using liquid-based cytology 
(Bae-Jump et al., 2007). The authors did not specifically report any unsatisfactory sample 
cases. In 2001, Levine and colleagues utilized a technique with a 2-cm nylon brush 
rotated over the vulva 20 times and then placed in tissue culture fluid and processed using 
a cytospin technique (Levine et al., 2001). All collected specimens were determined to 
have adequate cellularity. Maclean  (Maclean, 2006)also used the nylon brush technique 
but reported a 14% unsatisfactory rate due to low cellularity. Nauth and colleagues 
published a series of papers on vulvar cytology using a pre-moistened saline swab as the 
collection device (Nauth, 1981, 1986; Nauth & Boger, 1982; Nauth, Neumann, & Feilen, 
1987). This technique was successful throughout several studies. Kashimura et al. 
obtained cytological samples by vigorously scraping the edge of a slide against the tissue 
after application of saline solution to avoid drying (Kashimura, Matsuura, Kawagoe, 
Toki, & Sugihara, 1993). The authors did not indicate any problems due to lack of 
cellularity. With the development of liquid-based cytology, a nylon brush maybe the most 
appropriate collection technique, but research is needed to determine its adequacy with 
this methodology.  
 
Vulvar Cytology and Histology 
 Six studies were found that addressed the correlation of vulvar cytology to 
histology. Comparison across these studies are difficult due to the different analyses used, 
however, most studies reported high correlation up to 91% (Levine et al., 2001; Maclean, 
2006; Nauth, 1986). Levine and associates reported 100% sensitivity with no false 
negatives among a sample of 23 women; however, in a larger study (N= 123) by Nauth, 
up to 30% of benign conditions were reported as abnormal. In 56 samples, Jimenez-
Ayala and Jimenez-Ayala also reported no false negatives with a sensitivity of 96.7% for 
benign conditions and 98.12 for malignant conditions (Jimenez-Ayala & Jimenez-Ayala, 
2002). They also found high accuracy with 98.87% specificity for benign conditions and 
94.82% specificity for malignant conditions. In contrast, two studies found vulvar 
cytology not to be an accurate predictor for histology [13, 19]. Kashimure and colleagues 
provided data on vulvar cytology for 55 women with carcinoma of the vulva (Kashimura 
et al., 1993). They found 11% had a negative cytology result, 24% were reported as 
suspicious, and 65% were reported as positive; however findings for women with VIN 
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were not reported. The low rates for carcinoma of the vulva in this study may be 
attributed to the keratinization of the tissue, making exfoliation of the malignant cells 
difficult. The most recent study  reported only 32% of the 22 patients with biopsy proven 
disease had a positive vulvar cytology test result (Bae-Jump et al., 2007). Both of these 
studies utilized a scraping technique to obtain their sample. The most recent study was 
retrospective and therefore sampling errors may have occurred. Overall, vulvar cytology 
appears to correspond well to histology, however further studies are needed with 
standardization of collection techniques. 
 
Clinical Pathway Placement 
 Research has not been conducted on the role vulvar cytology could play in vulvar 
disease and screening. Previous studies have focused on technique, correlation with 
histology, and interpretation of cytology findings. However, clinical expertise can 
postulate the placement of vulvar cytology in order to evaluate its effectiveness. 
Screening all women with vulvar cytology does not seem feasible. The incidence of VIN 
has been reported as 2.1/100,000. This incidence is too small to justify a screening 
measure and the costs may outweigh the benefit from a health care policy perspective. 
However, it may be feasible for vulvar cytology to be utilized one of two ways: 1) for 
those who present with known risk factors for VIN and/or 2) as a screening tool for 
women with a history of VIN. Risk factors for VIN include: an abnormal cervical 
cytology, cigarette smoking, immunosuppression, multiple sexual partners, and a history 
of condyloma, gonorrhea, or herpes simplex (Al-Ghamdi et al., 2002; Brinton et al., 
1990; Kurman, Trimble, & Shah, 1992; Sherman et al., 1991). Women who have a 
compromised immune system due to disease or steroid use may be at greater risk for VIN 
and subsequent development of squamous cell carcinoma due to their potential inability 
to eradicate the HPV infection of the lower genital tract (Al-Ghamdi et al., 2002).  In 
addition, it has been found that approximately half of women with vulvar cancer have 
lichen sclerosis (Scurry, 1999); therefore, it is imperative that women with lichen 
sclerosis be screened at regular intervals for the development of vulvar cancer. Vulvar 
cytology could be an appropriate screening tool for women with these risk factors if an 
adequate universally accepted technique is found. 
 
 It may also be feasible to utilize vulvar cytology to screen women with a history 
of VIN. As described earlier, recurrence rates have been found to be as high as 52% 
(Hillemanns et al., 2006; Jones et al., 2005; Thuis et al., 2000). Vulvar cytology may not 
only save women from unnecessary vulvar biopsies, but may also be more cost effective. 
Vulvar cytology is one-fourth the cost of vulvar colposcopy. Studies need to be 
conducted to determine the cost-benefit ratio for utilizing vulvar cytology in the clinical 
pathway for evaluation of possible recurrence in these women. 
 
Conclusion 
 Cervical cytology is routinely used to screen for cervical cancer and has been 
extremely successful in reducing the rates of cervical cancer in industrialized countries. 
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Years ago, vulvar cytology was used more routinely, however its practice has been 
largely abandoned today due to issues with air drying, artifact, and inadequate number of 
cells for evaluation. Former studies showed promise for this screening method and the 
advent of liquid based cytology may resolve some of the issues related to artifacts and 
drying. This screening tool deserves to be re-evaluated due for the possible benefits it 
may provide. It could be a key factor in the early detection of lesions. Vulvar cytology is 
inexpensive and easily performed. A broader array of health care providers could utilize 
this screening method and would be more comfortable with this skill set than performing 
a biopsy. In addition, this may be more cost-effective than initially doing a vulvar biopsy. 
Further research should be conducted to answer these important questions.  
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CHAPTER 3.  METHODOLOGY 
As a feasibility study, the findings will help inform future research on sampling 
technique and accuracy of vulvar cytology. This study will assist in determining if the 
sampling technique is appropriate and if the knowledge of cytologic interpretation of 
specimens from the vulva is sensitive and specific to the disease state. These preliminary 
findings may further enhance clinical care by identifying a non-invasive, less-painful, and 
potentially more cost effective method for identifying recurrent disease in women with 
VIN than through tissue biopsy. This could enhance patient compliance for follow up 
evaluation, therefore potentially detecting disease earlier. The purpose of this study was 
to determine the feasibility and efficacy of developing a protocol for cytologic sampling 
of vulvar lesions in conjunction with HPV testing as a valid method to monitor disease 
status in women being treated and followed for VIN.  
 
Research Design 
 The study used a cross-sectional design to determine accuracy of cytology and 
HPV typing. In addition, correlation was performed among cytology, tissue biopsy, and 
HPV type in samples taken from women with a history of VIN as compared to a control 
group of samples. The specific aims and research questions were: 
 
 
Specific Aim 1 and Research Questions 
 
To determine the feasibility of a protocol for cytologic sampling of vulvar lesions. 
 
1.1 Does the vulvar sampling technique provide adequate cellularity for 
cytologic examination? 
1.2 What is the sensitivity of vulvar cytology? 
1.3 What is the specificity of vulvar cytology? 
1.4 What are the negative and positive predictive values of vulvar cytology? 
 
 
Specific Aim 2 and Research Questions 
 
To evaluate the efficacy of vulvar cytology in conjunction with Human 
Papillomavirus (HPV) testing as a valid method to evaluate recurrent or persistent vulvar 
intraepithelial neoplasia. 
 
2.1 What is the relationship between vulvar cytology results and HPV results? 
2.2 Can HPV testing in combination with vulvar cytology, while controlling for 
age, be utilized as a triage tool for pathology results? 
2.3 What is the accuracy of PCR analysis for HPV as a predictor of vulvar 
intraepithelial neoplasia?  
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2.4 If an association is found between cytology/HPV and pathology results, then 
determine if cytology in conjunction with HPV testing predict the biopsy 
outcome? 
 
Sample and Setting 
 The feasibility study included a total of 48 women, 33 of whom had a history of 
VIN and presented with a lesion (defined as an acetowhite change following application 
of acetic acid), and were scheduled for colposcopy with biopsy as part of their planned 
follow-up management.  The remaining 15 women had no prior history of VIN and no 
visible presentation of lesions and were used as controls. An additional set of “control” 
specimens were obtained from 15 of the women with a history of VIN from an area that 
is free from any visible lesions. Women placed in the control group were assumed to be 
negative for VIN if they do not have a HR HPV on HPV typing. For data analysis, a total 
of 7 specimen groups were developed under these two groups of women (Figure 2). 
 
 
 Inclusion criteria for the VIN group were: 
 
• female over the age of 18 and under the age of 65 
• a history of VIN who present with a visible lesion  
• scheduled for colposcopy and possible biopsy as part of their post-treatment 
management 
• ability to speak and read English 
 
 Inclusion criteria for the healthy control group were: 
 
• female over the age of 18 and under the age of 65 
• scheduled for colposcopy for cervical dysplasia 
• absence of any visible vulvar lesions 
• ability to speak and read English 
 
 Exclusion criteria for the VIN group included patients who present with no lesion 
at follow-up.  
 
Exclusion criteria for the health control group included: 
 
• a history of VIN  
• presentation of visible lesion on examination 
 
Inclusion criteria for the lesion sampled included the sample being deemed 
adequate by the processing laboratory. 
 
 Participants were recruited from an urban community colposcopy clinic. 
Approximately 80% of the clientele are minorities (approximately 70% African
 
 
 
 
Figure 2. Specimen groups
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American, 5% Hispanic, and 5% other) and have Medicaid. This site performs 6-8 vulvar 
colposcopies per month on women previously diagnosed with VIN. Participants in the 
VIN study group were recruited upon presentation to the clinic for a scheduled visit after 
the provider identified that they were eligible and willing to participate, provided a lesion 
was found that would necessitate biopsy as part of their scheduled management. Healthy 
patients used as controls were recruited upon presentation to the clinic for a scheduled 
visit for colposcopy after an abnormal Pap smear.  Following an explanation of the study, 
confidentiality procedures and patient rights were explained. All potential participants 
were told that they are not obligated to participate and their care would not be affected if 
they declined to participate. A written informed consent was obtained from the 
participant if they agreed to participate in the study. Laboratory specimens were sent to 
two separate facilities. Vulvar cytology and tissue specimens were sent to the local 
processing laboratory used by the clinical facility. This laboratory is local and is part of a 
national network of clinical laboratories that perform more than one million tests on 
approximately 400,000 specimens per day. The HPV samples were sent to an out of state 
laboratory that provides a full range of quality anatomic, pathology, and consultation 
services with expertise in HPV typing with the most sensitive HPV primer (PGMY 
09/11). 
 
Study Procedures 
 All participants in the VIN group received liquid based cytology with HPV testing 
in addition to their scheduled vulvar biopsy. In 15 of these women, an additional control 
sample of cytology and HPV testing was taken from an area clinically free from a vulvar 
abnormality. Participants placed in the healthy control group (n=15) received liquid based 
cytology and HPV testing only of the vulva. Accuracy was based on sensitivity, 
specificity and predictive value of the liquid based cytology interpretation and HPV 
results in relation to the final histologic diagnosis (if tissue biopsy was done) or 
participant control status. Since tissue biopsy, as a gold standard, was not available from 
the controls (healthy and VIN controls), they were assumed to be VIN free if they did not 
have an IR or HR HPV on HPV testing. If they were IR or HR HPV positive, they were 
excluded as a control since it could not be confirmed if they truly did not have a VIN 
lesion that was missed during examination.  
 
 
Specimen Collection 
  
Colposcopy of the vulva was performed with the application of 5% acetic acid to 
the vulva (covering all areas including the rectum) for at least 3-5 minutes. Visual 
inspection along with a colposcope at 4x magnification was used to identify any 
acetowhite lesions.  
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Cytology and Human Papillomavirus  
  
The identified acetowhite lesion was anesthetized with injectable lidocaine and 
sampled for cytology by scraping cells from the surface of the lesion with a cytobrush 
collection device that was pre-moistened with sterile saline. This was done two times in 
order to have samples for cytology and HPV typing. The cytology sample was labeled 
specimen A and the HPV specimen was labeled B. A different cytobrush and vial was 
used for each lesion identified as needing a biopsy per clinical judgment. The cytobrush 
devices were then placed into a vial of PreservCyt® solution for transported to the lab 
facility. After collection of the cytology sample, a tissue biopsy was performed as part of 
the regular planned management for the patient. To ensure correlation with cytology, the 
tissue collected was placed in formalin and transported to the same laboratory facility as 
the cytology specimen.  The procedure described above was also carried out in an area of 
the vulva that is free from any visible lesions for patients who had a history of VIN and 
presented with a lesion within another area of the vulva. This procedure was also 
conducted on healthy controls from the labia majora.  
 
 Once received in the laboratory, the PreservCyt® vial for cytology was processed 
using the ThinPrep® processor, stained with Papanicolaou stain, and cover slipped. A 
certified cytotechnologist,  obtained the specimen from the laboratory facility for 
evaluation under a light microscope. The specimen was evaluated for adequacy and 
screened for any abnormalities indicating a malignant or pre-malignant condition. 
Appropriate cells were  identified by marking with a pen and a preliminary interpretation 
made. The specimen was forwarded to a board certified cytopathologist for final 
interpretation and reporting of the cytologic diagnosis. The same cytopathologist 
interpreted all of the specimens for this study. 
 
 Specimen vial B was sent to a separate laboratory facility for PCR detection of 
HPV. Specimens testing positive for HPV detection, were automatically reflexed to PCR 
identification of high and low risk HPV types.  PCR is a selective target amplification 
assay that generally has a sensitivity of 1-10 copies per PCR reaction. The PGMY09/11 
primer was utilized. This primer has the most sensitivity (80-90%) of the primers for 
detecting multiple HPV infection (Fuessel et al., 2003; Klug et al., 2008; Nonogaki et al., 
2004; Qu et al., 1997). This primer amplifies the conservative L1 region of the HPV 
genome which generates a single DNA strand. This strand is of a particular prescribed 
molecular weight specific for each HPV type present. Restricted fragment length 
polymorphism (RFLP) analysis of the PCR products creates unique band patterns utilized 
in HPV type identification.  
 
 
Tissue Biopsy 
  
After collection of the cytology sample from the acetowhite lesion, a tissue biopsy 
was performed as part of the regular planned management for the patient. Tissue biopsy 
was conducted by cleaning the area with betadine (if not allergic) and anesthetizing with 
injected lidocaine. A 3-5mm keys punch biopsy was used to obtain the tissue specimen. 
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Homeostasis was achieved using silver nitrate. The patient was instructed not to rub the 
area and to keep clean and dry for one week. To ensure correlation with cytology, the 
tissue collected was placed in formalin and transported to the same laboratory facility as 
the cytology specimen. Upon receipt of the biopsy specimen(s) in the laboratory facility, 
the specimen was processed, stained with Hematoxylin and Eosin, and cover slipped. The 
cytopathologist  obtained the specimen for evaluation and diagnosis. The cytopathologist 
was blinded to the VIN status of participants. The histology report was sent to the 
patient’s provider to be included in the patient’s medical records.  
 
Data Analysis 
Demographic data of race and age was collected to describe the sample. Results 
of cytologic interpretation, HPV testing and biopsy diagnosis were recorded in an Excel 
database and imported into SAS for correlation and analysis using descriptive statistics. 
Since some participants selected as controls had an abnormal cytology or positive HPV 
test, further identification of controls occurred. A participant was removed as a control if 
they had a HR HPV identified and were not included in the data analysis for sensitivity, 
specificity, and predictive value of vulvar cytology and HPV testing. This resulted in 6 
participants being removed as controls from this portion of the analysis.  
 
To answer Aim 1.1, a proportion was used to determine if an adequate number of 
cytologic specimens had appropriate cellularity for examination. An adequate number of 
cells was defined as 3-4 cells per 40X high power field. The cytology must have been 
deemed adequate to have a cytologic interpretation appropriate for analysis. Nine 
specimens were deemed inadequate for evaluation and removed from further analysis.  
 
To answer Aim 1.2-1.4, cytology and HPV testing from VIN and healthy women 
were categorized as either positive or negative (Figure 2). Biopsy specimens were 
likewise categorized. For purposes of analysis, the gold standard for which cytology was 
compared was established by HPV- status (being negative for IR or HR HPV) or biopsy. 
The specimen was categorized as positive for the disease state if the biopsy was positive 
for VIN 1, 2 , or 3.The cytology specimen group was formed by including all cytology 
specimens from the VIN lesions, VIN-free lesions (in women with a history of VIN), and 
healthy controls. Cytology results of ASCUS or greater were considered positive and 
negative results remained negative. This resulted in four groups. These 4 groups (VIN +, 
VIN -, cytology +, or cytology -) were placed into a 2x2 table for analysis. Six specimens 
were removed due to a HR HPV in a control sample and an additional 9 specimens were 
removed due to lack of cellularity, leaving 67 total specimens for evaluation. Evaluation 
of the adequacy of vulvar cytology for VIN was then calculated.  
 
Sensitivity refers to the proportion  of positive test results that are truly positive. 
Specificity is the proportion of negatives that are truly negative. Positive predictive value 
was determined by evaluating the proportion of true positives among those reported 
positive. Negative predictive value was calculated by the proportion of true negatives 
Among those reported negative. 
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To answer Aim 2.1, HPV results were converted to categorical data of negative 
(0), low risk (1), intermediate risk/ high risk (2), and unknown (3).  A nonparametric test 
was used for the analysis since the sample was small and data were categorical. Fisher’s 
exact was used to determine the association of HPV results and cytology results.  
 
To answer Aim 2.2 a logistic regression was used with the biopsy outcome 
serving as the dependent variable (therefore only those with a tissue biopsy was included 
in the analysis) and the HPV/cytology results as the independent variable while 
controlling for age.  Age was controlled for since higher mean ages have been associated 
with vulvar cancer and well-differentiated VIN which tends to be more aggressive 
(Haefner, Tate, McLachlin, & Crum, 1995).  
 
To answer Aim 2.3, sensitivity, specificity, positive predictive value, and negative 
predictive value was calculated on HPV analysis as a predictor of VIN. HPV testing from 
VIN and healthy women were categorized as either positive or negative (Figure 2). 
Biopsy specimens were likewise categorized. For purposes of analysis, the gold standard 
for which cytology was compared was established by HPV- status (being negative for IR 
or HR HPV) or biopsy. The specimen was categorized as positive for the disease state if 
the biopsy was positive for VIN 1, 2 , or 3.The HPV specimen group was formed by 
including all HPV specimens from the VIN lesions, VIN-free lesions (in women with a 
history of VIN), and healthy controls. HPV results of IR or HR HPV were considered 
positive. LR and negative results remained negative. This resulted in four groups. These 4 
groups (VIN +, VIN -, HPV +, or HPV -) were placed into a 2x2 table for analysis. Six 
specimens were removed due to a HR HPV in a control sample, 1 specimen was removed 
because of an unknown HPV type, and an additional 16 specimens were removed due to 
lack of cellularity, leaving 59 total specimen samples for evaluation. Evaluation of the 
adequacy of vulvar cytology for VIN was then calculated.  
 
Aim 2.4 would have been answered using a ROC curve to determine the ability of 
cytology in conjunction with HPV testing to predict the outcome of VIN. Aim 2.4 would 
have only been conducted if an association was found between cytology/HPV and 
pathology results as completed for Aim 2.2. No power analysis was performed as this is a 
feasibility study of a rare disease. The planned number of participants is consistent with 
the number of subjects in other pilot studies in this area (Levine et al., 2001). 
 
Protection of Human Subjects 
 This study was approved by the University of Tennessee Health Science Center 
Institutional Review Board (see Appendix A). Potential study participants were identified 
by their healthcare provider to determine if they met the inclusion and exclusion criteria. 
If they met inclusion criteria, the study was explained in detail by a member of the 
research team and participants were provided with a copy of the consent form (see 
Appendix B). Potential participants were told that they were not obligated to participate 
and their care would not be affected if they declined to participate. After individuals 
reviewed the consent form at their leisure, the contents of the consent form were re-
18 
reviewed and any questions answered. Written consent was obtained and a copy of the 
signed consent form was given to the participant.  
 
 The risks associated with the cytologic sampling required for this study procedure 
included possible irritation from the cytobrush. The vulvar area was anesthetized prior to 
cytologic sampling to reduce the amount of discomfort experienced during the procedure.  
Risks associated with vulvar biopsy (the customary and usual practice for diagnosing 
vulvar lesions) include pain, bleeding, and infection. The participant was advised of the 
possibility of discomfort prior to consenting to the study and was advised to notify their 
healthcare providers if they experienced any vulvar problems. 
 
 The research record and specimens were labeled with a code number. A master 
key that linked the subject’s name to the code number was maintained in a separate and 
secure location.  The patient’s name and identifying information was used in accordance 
with standard policy for receipt of specimens in the laboratory. HIPAA authorization was 
included in the confidentiality section of the consent form. No individual identifying 
information will be used when conclusions and results are reported or presented for 
scientific review.   
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CHAPTER 4.  RESULTS AND CONCLUSIONS 
Introduction 
Vuvlar intraepithelial neoplasia (VIN), a rare skin condition that may lead to 
vulvar cancer, is increasing in incidence. Studies have found VIN has doubled in all age 
groups, but tripled in women under the age of 50 (Joura, Haider-Angeler, Breitenecker, & 
Leodolter, 2000; Sturgeon et al., 1992). In addition, vulvar cancer has increased by 20% 
in the United States between 1973 and 2000 (Judson et al., 2006). These increases are 
attributed to increasing rates of human papillomavirus (HPV), a sexually transmitted 
virus. The recurrence rate for VIN has been found to be as high as 35%. Currently the 
gold standard for evaluation of VIN recurrence is vulvar colposcopy and tissue biopsy. 
Although tissue biopsy is the gold standard, vulvar colposcopy is difficult to perform on 
the vulva. Acetowhite changes are non-specific and many health care providers are not 
well versed in performing this procedure. Various skin conditions may mimic VIN and 
therefore all lesions are typically subjected to tissue evaluation through biopsy. As a 
result, many women are subjected to tissue biopsies that may not be warranted. Tissue 
biopsy is painful and anxiety producing.  Women with VIN have specifically reported 
that stress and anxiety  accompany their clinical exams and anticipation of a vulvar 
biopsy (Likes et al., 2008). 
 
 Currently tissue biopsy is the only tool utilized in diagnosing VIN. The use of a 
triage test may decrease un-necessary painful tissue biopsies in these women who will 
undergo continuous evaluation with the possibility of many biopsies over their lifetime. 
Cytology (Pap smear) has been highly successful in the triage of patients with cervical 
cancer and cervical dysplasia, however in the past it has failed to show similar success 
rates on the vulva. This difficulty results from air drying, artifact, keratinization of the 
skin making interpretation difficult, and inadequate collection techniques to obtain 
sufficient numbers of cells for evaluation. However, with the development of liquid-
based cytologic technology, the use of vulvar cytology merits re-evaluation of this 
technique. Vulvar cytology offers several advantages of tissue biopsy in that it is less 
invasive, less painful, and may be more cost effective. In addition, vulvar cytology has 
the ability to sample a larger area of the vulva than the 3-4mm area taken by a punch 
biopsy. Therefore, the purpose of this pilot study was to determine the feasibility of 
cytologic sampling of vulvar lesions and to evaluate the efficacy of vulvar cytology in 
conjunction with HPV testing as a valid method for following women treated for VIN.  
Specific study aims and research questions were: 
 
 
Specific Aim 1 and Research Questions 
 
To determine the feasibility of a protocol for cytologic sampling of vulvar lesions. 
 
1.1 Does the vulvar sampling technique provide adequate cellularity for 
cytologic examination? 
1.2 What is the sensitivity of vulvar cytology? 
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1.3 What is the specificity of vulvar cytology? 
1.4 What are the negative and positive predictive values of vulvar cytology? 
 
 
Specific Aim 2 and Research Questions 
 
To evaluate the efficacy of vulvar cytology in conjunction with Human 
Papillomavirus (HPV) testing as a valid method to evaluate recurrent or persistent vulvar 
intraepithelial neoplasia. 
 
2.1 What is the relationship between vulvar cytology results and HPV results? 
2.2 Can HPV testing in combination with vulvar cytology, while controlling for 
age, be utilized as a triage tool for tissue biopsy results? 
2.3 What is the accuracy of PCR analysis for HPV as a predictor of vulvar 
intraepithelial neoplasia?  
2.4 If an association is found between cytology/HPV and tissue biopsy results, 
then determine if cytology in conjunction with HPV testing predict the 
biopsy outcome? 
 
Materials and Methods 
 A cross-sectional design was used to determine the correlation among cytology, 
tissue biopsy, and HPV type in women with a history of VIN and a clinically suspicious 
lesion as compared to a control group. Two sets of women were included in the control 
group. One set consisted of clinically apparent VIN- free women and the second set 
included samples from of an area clinically free of possible VIN in women with a history 
of VIN. The samples collected as control specimens were assumed to be negative for 
VIN if the HPV testing results were negative for HR HPV. If they were positive for HR 
HPV, they were excluded from analysis of sensitivity, specificity, and predictive value 
(n=6). Forty-eight women were recruited from a community colposcopy clinic and 
provided informed consent for this Institutional Review Board study, with a total of 82 
specimen collected for cytology/HPV. The patient population from this community 
colposcopy clinic includes a high percentage (approximately 35%) of 
immunocompromised patients, therefore at a higher risk for VIN and recurrence of VIN. 
Although a power analysis was not performed for this feasibility study, the number of 
participants is consistent with the number of participants in other pilot studies in this area 
(Levine, 2001).  
 
 After signed informed consent, vulvar colposcopy with 5% acetic acid and visual 
inspection was performed to assess the absence or presence of a clinically suspicious 
vulvar lesion. Once a clinically suspicious lesion was identified, it was anesthetized with 
injectable lidocaine and sampled for cytology by scraping the cells from the surface of 
the lesion with a saline moistened cytobrush collection device rotated 20 times. The 
procedure was repeated with a second cytobrush for HPV typing through PCR. The 
cytobrushes were placed in separate vials of PreservCyt® solution for transport to the 
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appropriate laboratory facility. Tissue biopsy of the lesion was then obtained using a 3-
5mm keys punch biopsy. In the control specimens, the same procedures were used, 
however the injection of lidocaine was not performed since no tissue biopsy was 
obtained. The pathologist and cytotechnologist were blinded to the VIN status of the 
participant. A total of 82 specimen groups were collected from these 48 women. Fifty-
two of these specimens were obtained from VIN-suspicious lesions in women with a 
history of VIN. An additional 15 specimens, to be used as controls, were taken from these 
women with VIN in an area of the vulva with no gross abnormalities. Additional control 
specimens were taken from 15 women with no history of VIN and no gross vulvar 
abnormalities. 
 
 The PreservCyt® vial for cytology was processed using the ThinPrep® processor, 
stained with Papanicolaou stain, and cover slipped. The specimen was screened for 
cellular adequacy and screened for possible malignant or premalignant abnormalities. A 
certified cytotechnologist and board certified cytopathologist provided a final cytologic 
interpretation. The second PreservCyt® vial was sent for PCR detection for HPV. If PCR 
testing was positive for HPV, the specimen was HPV typed using PGMY 09/11 primer. 
PGMY 09/11 primer has the most sensitivity (80-90%) of the primers and identifies 50 
HPV types through amplification of the L1 region of the HPV genome (Figure 3). 
 
Statistical Analysis 
 Results of cytologic interpretation, HPV testing, and biopsy diagnosis were 
recorded in an Excel database and imported into SAS for analysis using descriptive 
statistics. Since some specimens selected as controls had abnormal cytology or positive 
HPV tests, further identification of controls continued to occur until an adequate number 
of controls was obtained. A specimen was classified as a control and removed from 
further analysis of sensitivity, specificity, and predictive value if they had a HR HPV 
identified (n=6). These controls were assumed negative for VIN since tissue biopsy was 
not available. Sensitivity and specificity of cytology and HPV typing were compared to 
tissue biopsy and/or control (automatically assumed negative for disease) and placed in a 
2x2 table for analysis. Positive predictive values were determined by evaluating the 
proportion of true positives among those reported positive. Negative predictive values 
were determined by evaluating the proportion of true negatives among those reported 
negative. HPV results were converted into categorical values of negative, low risk, 
intermediate risk/high risk, or unknown and a Fisher’s Exact test used to determine the 
association of HPV and cytology results. If multiple HPV types were present, the 
specimen was coded with the highest risk HPV. For example, if a lesion had two LR 
HPV types and a HR HPV type, they were coded as HR HPV. A logistic regression with 
the biopsy result as the dependent variable and cytology/HPV results as the independent 
variables were used to determine if cytology in combination with HPV could be used as a 
triage tool for pathology results. Age was controlled for in this regression analysis since it 
has been found that with increasing age, VIN may be more aggressive. If an association 
would have been found between cytology/HPV results and pathology results, a ROC 
curve would have been performed.   
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 6  34  52  62  75 
11  35  53  64  77 
16  39  54  66  80 
18  40  55  67  81 
26  42  56  68  82 
30  43  57  69  83 
31  44  58  70  84 
32  45  59  72  CP6108 
33  49  60  73  CP8061 
33  51  61  74  LVX160 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: HPV types by PGMY 09/11 premier 
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Results 
 The study consisted of 82 samples from 48 women with a mean age of 34 (range 
19-65).  Demographics of each group can be found in Table 1. Of the 52 tissue samples, 
32 (62%) were reported as VIN I. ASCUS and VIN I were each reported in 33% (n=27) 
of cytology samples. The cytology, HPV, and when appropriate, histology results from 
the 82 lesions are reported in Table 2.  
 
Cytology results are reported as quantity not sufficient (QNS), negative, ASCUS, 
ASCUS favor VIN 1,VIN 1, VIN 1/VIN 2, VIN 2, or VIN 2/VIN 3. The HPV results are 
reported as negative, low risk, intermediate risk/ high risk, or unknown. When coding for 
HPV status, the HPV result with the highest risk was deferred to for each lesion. For 
example, if a lesion had two LR HPV types and one HR HPV type identified, the lesion 
was coded as positive for HR HPV. Pathology, when available, is reported as negative 
(defined as non-dysplastic and includes hyperplasia), VIN I (including condyloma), VIN 
II, or VIN III. Since some specimens selected as controls had positive HR HPV tests, 
further identification of controls was conducted. A specimen was classified as a control if 
they had a negative biopsy or were HR HPV negative. The control specimens that were 
positive for a HR HPV were not used in the data analysis for sensitivity, specificity, or 
predictive value. This resulted in 6 specimens being excluded from these analyses. 
 
 
Aim 1.1: Adequacy 
 
 An adequate number of cells for cytologic interpretation were defined as 3-4 cells 
per 40X high power field. An adequate number of cells for cytologic samples were found 
in 90% (74 of 82) of samples. Adequacy was less frequent for HPV PCR with 72% (59 of 
82) samples being adequate for evaluation.  
 
 
Aims 1.2-1.4 and Aim 2.3: Sensitivity, Specificity and Predictive Value 
 
Of the 82 specimens, 68 were available for evaluation of vulvar cytology 
specificity, sensitivity, and predictive value, 8 were inadequate for evaluation due to lack 
of cellularity, and 6 were removed from analysis due to the control returning positive for 
a HR HPV. Vulvar cytology achieved a sensitivity of 95% with a trade-off of only 15% 
specificity. Positive and negative predictive value was 65% (40 true positives and 22 
false positives) and 67% respectively (4 true negatives and 2 false negative). HPV PCR 
achieved 62% sensitivity and 85% specificity. Positive and negative predictive value was 
89% ( 24 true positives and 3 false positives) and 53% (17 true negative and 15 false 
negatives) respectively. The 2x2 tables used for sensitivity and specificity can be found in 
Tables 3 and 4. 
 
Table 1.  Demographics 
 
Demographics All Women VIN Controls 
Age    
      Mean (range) 34 (19-65) 35 (19-65) 33 (19-62) 
Ethnicity (n)    
      African 
American 43 31 25 
      Caucasian 4 1 5 
      Other 1 1 0 
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Table 2.  Participant lesion results 
Participant 
# 
Lesion 
# 
Cytology HPV  Tissue Biopsy 
1 1 QNS* Negative Squamous hyperplasia 
1 2 QNS QNS VIN 1 
2 3 VIN 1 HR* VIN 1 
2 4 Negative HR VIN 1 
2 5 ASCUS-favor VIN 1 HR VIN 1 
2 6 ASCUS QNS NA 
2 7 ASCUS Unknown VIN 1 
3 8 ASCUS- favor VIN 1 Negative VIN 1 
4 9 VIN 1/VIN 2 HR VIN 2 
4 10 VIN 1 HR VIN 1 
5 11 VIN 1/VIN 2 HR VIN 3 
5 12 QNS HR VIN 2 
5 13 VIN 1/VIN 2 LR VIN 2 
6 14 Negative HR VIN 1 
6 15 VIN 1 HR Negative 
7 16 VIN 1 Negative VIN 1 
8 17 VIN 1 HR VIN 1 
8 18 VIN 1 HR VIN 1 
9 19 VIN 1 Negative VIN 1 
10 20 VIN 1 Negative VIN 1 
11 21 VIN 1 LR* VIN 1 
11 22 VIN 1 LR VIN 1 
12 23 VIN 1 LR VIN 1 
12 24 VIN 1 LR VIN 1 
12 25 ASCUS LR Hyperplasia 
12 26 ASCUS LR NA* 
13 27 VIN 1 HR VIN 1 
14 28 ASCUS Negative VIN 1 
15 29 VIN 1/ VIN 2 Negative VIN 1 
16 30 VIN 1 LR VIN 1 
16 31 ASCUS QNS VIN 1 
16 32 ASCUS Negative NA 
17 33 VIN 1 HR VIN 1 
18 34 VIN 1/ VIN 2 LR VIN 1 
19 35 ASCUS QNS Negative 
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Table 2. (continued) 
Participant 
# 
Lesion 
# 
Cytology HPV  Tissue Biopsy 
19  37 QNS QNS VIN 1 
19  38 QNS QNS NA 
20 39 ASCUS favor VIN 1 HR Hyperplasia 
20 40 ASCUS HR NA 
20 41 QNS Negative VIN 1 
21 42 VIN 1/ VIN 2 HR VIN 2 
21 43 VIN 1 HR VIN 1 
21 44 ASCUS QNS NA 
22 45 VIN 1 Negative NA 
23 46 Negative Negative NA 
24 47 VIN 1/ VIN 2 HR VIN 1 
24 48 VIN 1 LR NA 
25 49 VIN 1 HR VIN 1 
25 50 VIN 1 HR NA 
26 51 ASCUS HR VIN 2 
26 52 VIN 1 HR VIN 1 
27 53 Negative QNS NA 
28 54 ASCUS LR NA 
29 55 ASCUS LR NA 
30 56 ASCUS Negative NA 
31 57 ASCUS QNS VIN 2 
32 58 VIN 1/ VIN 2 Negative Negative 
33 59 VIN 1 HR VIN 2 
33 60 ASCUS LR VIN 2 
34 61 ASCUS Negative Hyperplasia 
34 62 ASCUS QNS NA 
35 63 VIN 1 IR* VIN 1 
35 64 QNS QNS NA 
36 65 Negative LR NA 
37 66 VIN 1 LR NA 
38 67 VIN 1/ VIN 2 HR NA 
38 68 VIN 2/ VIN 3 HR VIN 3 
39 69 ASCUS Negative NA 
40 70 Negative Negative NA 
41 71 ASCUS HR NA 
27 
Notes: *QNS= quantity not sufficient for evaluation; HR= high risk HPV; IR= 
intermediate risk; LR= low risk HPV; NA= was a control and no biopsy collected 
Table 2. (continued) 
Participant 
# 
Lesion 
# 
Cytology HPV  Tissue Biopsy 
42 72 VIN 1 HR NA 
43 73 ASCUS HR VIN 2/ VIN 3 
43 74 ASCUS HR NA 
44 75 VIN 1 Negative NA 
45 76 VIN 2/ VIN 3 HR VIN 3 
45 77 VIN 1/ VIN 2 HR NA 
45 78 VIN 1/ VIN 2 HR VIN 3 
46 79 VIN 1/ VIN 2 QNS VIN 1 
46 80 QNS QNS NA 
47 81 ASCUS QNS NA 
48 82 VIN 1 QNS NA 
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Table 3.  Comparison of cytology test results to biopsy results 
Cytology Biopsy Total 
 
 Positive Negative  
Positive 40 (TP) 22 (FP) 62 
Negative 2 (FN) 4 (TN) 6 
Total 42 26 68 
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Table 4.  Comparison of HPV test results to biopsy results 
HPV Biopsy Total 
 Positive Negative  
Positive 24 (TP) 3 (FP) 27 
Negative 15 (FN) 17 (TN) 32 
Total 39 20 59 
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Aim 2.1 and 2.2: Association of Cytology to HPV PCR / Pathology 
 
 After categorizing cytology results into 4 categories (negative, ASCUS, LGSIL, 
or HGSIL) and HPV PCR into 4 categories (negative, low risk, intermediate risk/ high 
risk, and unknown) no association was found between these variables (p=0.3559). A 
logistic regression analysis was performed, controlling for age, with pathology result as 
the dependent variable and cytology and HPV PCR as the independent variables. 
Utilizing forward selection, cytology and HPV PCR were not found to be predictors for 
pathologic diagnosis of VIN (p>.05) and fell from the logistic model.  
 
Discussion and Conclusions 
Both the incidence of VIN and vulvar cancer has been increasing. As more 
women are experiencing the anxieties and risks associated with VIN surveillance and 
possible recurrence, it is critical to evaluate novel techniques that may decrease their 
anxiety and facilitate the early identification of recurrent or persistent disease.  The 
collection technique utilized in this study provided for adequate cellularity in the majority 
of the swabs (90% for cytology and 72% for HPV PCR).  The cytology adequacy rate 
from this method of collection is consistent with the literature (Levine et al., 2001; 
Maclean, 2006), however the adequacy rate for HPV was slightly lower than that for the 
cytology specimens.  This difference may have been influenced by the fact that brush 
sample for the HPV PCR lab was collected following collection of the sample for 
cytology lab.  The cellular material may be more difficult to obtain with the second swab, 
thus decreasing the adequacy rate in the HPV PCR samples.  This study found that by 
vigorous brushing with a cyto brush pre-moistened with saline, it is possible to obtain an 
adequate cellular sample from the vulva for cytologic and/or molecular evaluation for 
HPV. Previous problems with air drying or harvesting cells were not an issue in this 
study. 
 
 The sensitivity of vulvar cytology was high at 95%, however the specificity was 
low (15%). Vulvar cytology also had a low positive predictive value at 65%. Although, 
vulvar cytology identified the majority of abnormalities, the specificity of the test would  
yield a substantial number of false positives. This means that the use of cytology would 
not spare women the need for biopsy. The specificity may be improved through 
development of standardized criteria for classifying vulvar cytologic specimens. 
However, this has yet to be shown and should be investigated further. Sensitivity and 
specificity was moderate to high in range for HPV PCR (62% and 85% respectively).  
Neither cytology nor HPV were found to be predictors for the diagnosis of VIN. This 
may be due to the specificity issues with vulvar cytology. Again, this may be different 
with more stringent and clearer criteria for classifying vulvar cytology specimens.  
 
 It was of additional interest to evaluate the utility of combining cytology and 
HPV. If a cytology returned ASCUS, the HPV results were utilized as a reflux test to 
determine if cytology would be deemed positive or negative. A HPV result of HR HPV 
resulted in a interpretation of positive cytology, thus ultimately leading to the impression 
of a needed biopsy. A HPV result of negative or LR HPV was interpreted as a negative 
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cytology finding. Fifty-six samples were available for analysis. The sensitivity was 90%, 
specificity 61%, PPV 83%, and NPV 73% (Table 5). The specificity improved, however 
this was at the expense of sensitivity.  
 
 The results of this study may be underestimated due to the selection of controls 
and the absence of a tissue biopsy in these women to confirm the absence of HPV. Eight 
of the 27 controls had a LR HPV that did not exclude them as a control. Field effect from 
their HPV infection may have caused an HPV effect on the vulva, leading to an ASCUS 
or VIN cytology finding. Without tissue biopsy, this factor and its effect on the 
specificity of this study could not be verified. However, cytology did not miss any of the 
VIN 2 or VIN 3 samples. From a clinical perspective, this is critical because we do not 
treat VIN 1 since it is an overcalled and non-reproducible finding and thought to be a 
common condition that does not lead to cancer in the majority of women. All the women 
in the study with VIN 2 or VIN 3 would have been discovered through cytology and 
treatment initiated. The major limitation of vulvar cytology at this time is specificity and 
the high false positive rate if, in fact, no “filed effect” is present. This would lead to 
unnecessary biopsies in these women and decrease the clinical utility of vulvar cytology 
for surveillance of women with VIN.   
 
 In conclusion, because of the anxiety and discomfort related to vulvar biopsy, and 
the frequency with which biopsies are required to monitor women with a history of VIN, 
continued evaluation of vulvar cytology in the context of liquid based cytology is 
warranted. Although this study found positive results with regard to sensitivity, the 
specificity was poor and did not demonstrate a role for vulvar cytology at this time. 
However, our study size was limited by the small size. A larger study, after identifying a 
clearer classification profile for vulvar cytology and confirming the absence of disease, 
would be important to better address the needs of this growing patient population. 
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Table 5.  Comparison of cytology/HPV reflux test results to biopsy results 
Cytology/ HPV Biopsy Total 
 Positive Negative  
Positive 34 (TP) 7 (FP) 41 
Negative 4 (FN) 11 (TN) 15 
Total 38 18 56 
Notes: Sensitivity= 90%; Specificity= 61%; PPV= 83%; NPV= 73% 
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